Search
Cisplatin Treatment Options in Texas
A collection of 537 research studies where Cisplatin is the interventional treatment. These studies are located in the Texas, United States. Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-small Cell Lung Cancer.
505 - 516 of 537
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have limited-stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2012
Locations: Veterans Affairs Medical Center - Dallas, Dallas, Texas +8 locations
Conditions: Lung Cancer
S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx
Terminated
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. It is not yet known whether giving combination chemotherapy together with radiation therapy is more effective than giving cisplatin togeth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +5 locations
Conditions: Head and Neck Cancer
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
Completed
Primary Objective:
1. Assess the clinical activity defined by response rate of irinotecan and cisplatin in untreated patients with metastatic or unresectable high grade neuroendocrine carcinoma of the gastrointestinal tract.
Secondary Objective:
1. To assess the safety profile of irinotecan and cisplatin in untreated patients with metastatic or unresectable high grade neuroendocrine carcinoma of the gastrointestinal tract.
Gender:
ALL
Ages:
All
Trial Updated:
08/01/2012
Locations: U.T. M.D. Anderson Cancer Center, Houston, Texas
Conditions: Gastrointestinal Cancer, Carcinoma, Neuroendocrine
Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
Completed
The goal of this clinical research study is find the highest safe dose of cisplatin that can be given with liposomal doxorubicin in the treatment of advanced cancer involving the liver.
PRIMARY Objectives:
To determine the toxicity and safety of a monthly cytotoxic regimen combining intraarterial hepatic (HAI) cisplatin with systemic intravenous liposomal doxorubicin in patients with cancer metastatic to the liver.
SECONDARY Objectives:
To document in a descriptive fashion the antitumor effi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/01/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/27/2012
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
Completed
Primary Objective:
-To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
Gender:
MALE
Ages:
14 years and above
Trial Updated:
07/27/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Penile Cancer
Taxotere/Temodar/Cisplatin Study in Melanoma Patients
Completed
Primary Objective:
1. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma.
Secondary Objectives:
1. To determine the toxicity of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma
2. To determine the response rate of induction chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Melanoma
S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of tirapazamine plus cisplatin in treating patients who have metastatic, recurrent, or refractory cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/13/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +6 locations
Conditions: Cervical Cancer
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +7 locations
Conditions: Lung Cancer
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin is more effective when combined with paclitaxel or gemcitabine in treating cervical cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with paclitaxel to that of cisplatin combined with gemcitabine in treating women who have recurrent, persi... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
06/11/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +9 locations
Conditions: Cervical Cancer
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
Completed
Primary:
1. To evaluate the preliminary efficacy of palifermin in reducing the incidence and severity of oral mucositis (OM) in patients with sarcoma receiving multicycle chemotherapy.
2. To evaluate the pharmacokinetics (PK) of palifermin when given pre chemotherapy.
3. To evaluate the safety profile of palifermin when combined with multicycle chemotherapy.
Exploratory:
1. To evaluate the biologic effect of palifermin on oral mucosa.
2. To investigate potential biomarker development by bioch... Read More
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
04/17/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Sarcoma, Oral Mucositis
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Completed
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2012
Locations: Pfizer Investigational Site, Houston, Texas
Conditions: Neoplasms
505 - 516 of 537